- Merck Millipore invests €12 million in Molsheim, France facility.
- Investment includes new clean room and two additional production lines.
- Centralizing R&D labs to form an Innovation Center.
- Molsheim site employs approximately 1,030 people since 1972.
Investment Overview
Merck Millipore, the Life Science division of Merck, has announced a €12 million investment in its Molsheim, France facility. This investment aims to expand the manufacturing capabilities for Ready-To-Use (RTU) Media, ensuring a reliable supply for customers in the region and supporting the heipha/Hycon product lines.
Facility Enhancements
The investment includes the extension of manufacturing capacity space for RTU Media, the addition of a new clean room, and the installation of two additional production lines. These enhancements will complement the existing production capabilities at the Eppelheim, Germany site.
Innovation Center
As part of the investment, current research and development laboratories across various scientific areas will be centralized to form an Innovation Center. This center will focus on developing solutions to meet future customer needs.
Global Market Demand
The increased manufacturing capacity will serve the growing global market demand and ensure sufficient capacity to support market growth. Merck Millipore acquired the heipha/Hycon product lines in 2011 through the purchase of Biotest AG, expanding its offerings in industrial microbiology.
Molsheim Site
Since its opening in 1972, the Molsheim facility has been a significant location for Merck Millipore. The site employs approximately 1,030 people and manufactures products across Merck Millipore’s BioMonitoring, Lab Water, and BioPharm Process Solutions Business Fields.
